RxDoctor Payments DataLook up a doctor →

George Isa, MD

Interventional Cardiology · Covington, LANPI 1588627533

Payments from drug & device makers

$80,860in general payments, 2019–2025

Across 646 payments — averaging $125.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$19K
  • Medtronic$17K
  • Shockwave Medical, Inc$9K
  • Sanofi-aventis U.S. LLC$8K
  • Penumbra, Inc.$7K
  • Regeneron Healthcare Solutions, Inc.$5K
  • plus $16K from 28 others
$2,000in research payments, 2019–2025

Across 1 payment — averaging $2000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$2K

What the payments were for

  • Consulting fees$9,01011%
  • Speaking & faculty fees$18,00722%
  • Travel & lodging$29,05336%
  • Food & beverage$24,79031%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$80,860 in reported general payments places this provider in the 80th percentile of 171 interventional cardiology providers in Louisiana.

See all interventional cardiology providers in Louisiana

Medicare billing

Part B allowed, 2024
$183,309
Medicare patients
936
Services billed
2,641

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban460$497,703
Repatha SureclickEvolocumab230$137,858
XareltoRivaroxaban101$71,533
EntrestoSacubitril/Valsartan49$68,626
NexlizetBempedoic Acid/Ezetimibe40$32,674
Praluent PenAlirocumab50$29,800
Ezetimibe740$12,619
Metoprolol Succinate781$10,121
ClopidogrelClopidogrel Bisulfate995$9,537
LivaloPitavastatin Calcium18$8,442
Valsartan277$8,087
VascepaIcosapent Ethyl18$7,686
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide248$7,246
Diltiazem 24hr Er (Cd)Diltiazem Hcl279$6,873
Rosuvastatin Calcium618$6,665

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$155$497,703460 claims
Johnson & JohnsonXarelto$62$71,533101 claims
NovartisEntresto$93$68,62649 claims
Esperion Therapeutics, Inc.Nexlizet$105$32,67440 claims
AstraZenecaBrilinta$237$5,95112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 171 interventional cardiology providers in Louisiana.

Other interventional cardiology in Covington

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →